← Calendar
Readoutin 165d
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264
Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.
- Date
- May 2027
- Type
- Readout
- Indication
- Non-Small Cell Lung Cancer
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Dec2026
Readoutin 14d
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Nov2026
ReadoutIn window
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — A166Phase 3 primary completion: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy.